{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:04:39Z","timestamp":1791821079641,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.10.015","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:12:49Z","timestamp":1761127969000},"page":"e325-e334.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-9181","authenticated-orcid":false,"given":"Shyam","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3961-3020","authenticated-orcid":false,"given":"Mili","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-4710","authenticated-orcid":false,"given":"Poorva","family":"Gurjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Dhamne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmalya Roy","family":"Moulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Chichra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-3176","authenticated-orcid":false,"given":"Dhanalaxmi","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papagudi G.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shripad","family":"Banavali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2025.10.015_bib0001","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.clml.2025.10.015_bib0002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2017.11.001","article-title":"When the good go bad: mutant NPM1 in acute myeloid leukemia","volume":"32","author":"Kunchala","year":"2018","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.clml.2025.10.015_bib0003","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.10.015_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0268-7","article-title":"Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia","volume":"10","author":"Xu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.10.015_bib0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2006-07-012252","article-title":"Acute myeloid leukemia carrying cytoplasmic\/mutated nucleophosmin (NPMc+ AML): biologic and clinical features","volume":"109","author":"Falini","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.10.015_bib0006","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.10.015_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01103-w","article-title":"Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia","volume":"14","author":"Yao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.clml.2025.10.015_bib0008","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO-24-01715","article-title":"Influence of nucleophosmin (NPM1) genotypes on outcome of patients with AML: an AIEOP-BFM and COG-SWOG intergroup collaboration","volume":"43","author":"Tregnago","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.10.015_bib0009","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.10.015_bib0010","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2015.133819","article-title":"Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia","volume":"101","author":"Alpermann","year":"2016","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clml.2025.10.015_bib0011","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"09","key":"10.1016\/j.clml.2025.10.015_bib0012","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fonc.2019.00450","article-title":"Utility of immunophenotypic measurable residual disease in adult acute myeloid leukemia-real-world context","volume":"13","author":"Patkar","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.015_bib0013","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.10.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30791","article-title":"KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1","volume":"71","author":"Srinivasan","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"10.1016\/j.clml.2025.10.015_bib0015","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3 \/ITD+ acute myeloid leukemia: a report from the children\u2019s oncology group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.015_bib0016","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"Engl J Med"},{"issue":"93","key":"10.1016\/j.clml.2025.10.015_bib0017","doi-asserted-by":"crossref","first-page":"36616","DOI":"10.18632\/oncotarget.26400","article-title":"Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia","volume":"9","author":"Patkar","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clml.2025.10.015_bib0018","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/leu.2008.313","article-title":"Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML","volume":"23","author":"Hollink","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.10.015_bib0019","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The incidence and clinical significance of nucleophosmin mutations in childhood AML","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.10.015_bib0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0019-509X.55546","article-title":"Epidemiology of childhood cancer in India","volume":"46","author":"Arora","year":"2009","journal-title":"Indian J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.10.015_bib0021","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2005-03-0899","article-title":"Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype","volume":"106","author":"Cazzaniga","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.015_bib0022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.leukres.2018.11.016","article-title":"Impact of NPM1 mutation subtypes on treatment outcome in AML: the Lyon-University Hospital experience","volume":"76","author":"Heiblig","year":"2019","journal-title":"Leuk Res"},{"issue":"25","key":"10.1016\/j.clml.2025.10.015_bib0023","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2018-01-828467","article-title":"High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML","volume":"131","author":"Patel","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.10.015_bib0024","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25544","article-title":"High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia","volume":"94","author":"Patel","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.015_bib0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MPH.0000000000002876","article-title":"Transforming childhood AML care in India","volume":"46","author":"Srinivasan","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.015_bib0026","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.10.015_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:44:31Z","timestamp":1780991071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042521"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}